Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease

被引：56

作者：

Kantarci K. ^{[1
]}

Jack Jr. C.R. ^{[1
]}

机构：

[1] Department of Radiology, Mayo Clinic, Rochester

来源：

NeuroRX | 2004年 / 1卷 / 2期

基金：

美国国家卫生研究院;

关键词：

Alzheimer's disease; magnetic resonance imaging; magnetic resonance spectroscopy; mild cognitive impairment; surrogate marker; volumetry;

D O I：

10.1602/neurorx.1.2.196

中图分类号：

学科分类号：

摘要：

Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：196 / 205

页数：9

共 103 条

[1]

Shoghi-Jadid K., Small G., Agdeppa E., Et al., Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer's disease, Am J Geriatr Psychiatry, 10, pp. 24-34, (2002)

[2]

Bacskai B., Hickey G., Skoch J., Et al., Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice, Proc Natl Acad Sci USA, 100, pp. 12462-12467, (2003)

[3]

Braak H., Braak E., Neuropathological staging of Alzheimer's disease, Acta Neuropathol (Berl), 82, pp. 239-259, (1991)

[4]

Seab J., Jagust W., Wong S., Et al., Quantitive NMR measurements of hippocampal atrophy in Alzheimer's disease, Magn Reson Med, 8, pp. 200-208, (1988)

[5]

Kesslak J., Nalcioglu O., Cotman C., Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease, Neurology, 41, pp. 51-54, (1991)

[6]

Jack Jr. C., Petersen R., O'Brien P., Tangalos E., MR based hippocampal volumetry in the diagnosis of Alzheimer's disease, Neurology, 42, pp. 183-188, (1992)

[7]

Convit A., de Leon M., Golomb J., Et al., Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation, Psychiatr Q, 64, pp. 371-387, (1993)

[8]

Frisoni G., Bianchetti A., Geroldi C., Trabucchi M., Measures of medial temporal lobe atrophy in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 57, pp. 1438-1439, (1994)

[9]

Lehericy S., Baulac M., Chiras J., Et al., Amygdalohippocampal MR volume measurements in the early stages of Alzheimer's disease, AJNR Am J Neuroradiol, 15, pp. 927-937, (1994)

[10]

de Leon M., George A., Golomb J., Et al., Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease, Neurobiol Aging, 18, pp. 1-11, (1997)

← 1 2 3 4 5 6 7 8 9 10 →